SCHEMBL26580321

SCHEMBL26580321

COC(=O)c1cc(F)c(O)cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.44
CA2 P00918 5/20 0.44
CA9 Q16790 5/20 0.44
CA12 O43570 4/20 0.44
CA7 P43166 4/20 0.44
CA14 Q9ULX7 4/20 0.44
PDK2 Q15119 1/20 0.44
PDK4 Q16654 1/20 0.44
SOS1 Q07889 1/20 0.44
LMNA P02545 3/20 0.44
GAA P10253 2/20 0.44
XDH P47989 2/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
NFKB1 P19838 1/20 0.44
GFER P55789 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
FUT7 Q11130 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709908 0.87 SOS1 (0.47) CA1CA2CA9CA12CA7
SCHEMBL1044548 0.86 CA1 (0.49) CA1CA2CA9CA12CA7
SCHEMBL14349262 0.85 SOS1 (0.50) CA1CA2CA9CA12CA7
SCHEMBL25342477 0.85 CA12 (0.50) CA1CA2CA9CA12CA7
SCHEMBL17782390 0.85 CA1 (0.50) CA1CA2CA9CA12CA7
SCHEMBL31024702 0.85 CA12 (0.50) CA1CA2CA9CA12CA7
SCHEMBL23906095 0.83 CA12 (0.48) CA1CA2CA9CA12CA7
SCHEMBL21352107 0.82 SOS1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL1512455 0.81 KDM4E (0.46) SOS1LMNAGAAKDM4EPOLB
SCHEMBL25381612 0.81 ALPL (0.43) SOS1LMNAGAAPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008760-A1 DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF INSMED INCORPORATED 2026-01-08 US disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN CA1 828/4885CA2 3529/4885CA9 1812/4885
US-20260008760-A1 DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF DPP9, DPP7, DPP4 CA1 211/4885CA2 253/4885CA9 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.